{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:26:51Z","timestamp":1793014011094,"version":"4.5.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"40","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021515","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021515","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016545","name":"Roche Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>After acute coronary syndrome (ACS), high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) levels have been associated with risk of major adverse cardiovascular events (MACE). Whether the prognostic information provided by hsCRP and IL-6 is independent and complementary after ACS is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The ODYSSEY OUTCOMES trial compared alirocumab with placebo in post-ACS patients on optimized statin therapy. In post hoc analyses, the relation between log-transformed hsCRP and IL-6 levels and risk of MACE and all-cause death was assessed in proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 11 817 patients had baseline hsCRP and IL-6 data; 1306 had a MACE primary endpoint and 458 died. Median hsCRP, IL-6, and low-density lipoprotein cholesterol (LDL-C) were 1.54 mg\/L, 5.00 pg\/ml, and 86 mg\/dl, respectively. hsCRP and IL-6 had moderate correlation (r = 0.52). In models for one biomarker adjusted for the other biomarker, treatment assignment, age, sex, diabetes, LDL-C, and time since index ACS, hsCRP was a significant independent predictor of MACE (P &amp;lt; .0001) and IL-6 was not (P = .21); both independently predicted death (P &amp;lt; .0001 for hsCRP and P = .0003 for IL-6). Relationships did not depend on treatment (all Pinteraction &amp;gt; .25). When dichotomized at 2 mg\/L (hsCRP) and 5 pg\/ml (IL-6), risks of MACE and death were significantly elevated when both, but not when one marker was elevated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with recent ACS, hsCRP independently predicted MACE, while both hsCRP and IL-6 predicted death. Together, the two markers provided complementary prognostic information. hsCRP conveys independent information on inflammatory risk beyond that provided by IL-6.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehag317","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:39:10Z","timestamp":1775907550000},"page":"6008-6017","source":"Crossref","is-referenced-by-count":4,"title":["Interleukin-6 and C-reactive protein prognostic value following acute coronary syndrome"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3246-8359","authenticated-orcid":false,"given":"Johan Wouter","family":"Jukema","sequence":"first","affiliation":[{"name":"Department of Cardiology, Leiden University Medical Center, PO Box 9600, Leiden 2300 RC, The \u00a0","place":["Netherlands"]},{"name":"Netherlands Heart Institute, Postbus 19258, 3501 DG Utrecht, The \u00a0","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas J","family":"Van Neer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leiden University Medical Center, PO Box 9600, Leiden 2300 RC, The \u00a0","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Szarek","sequence":"additional","affiliation":[{"name":"School of Public Health, Suny Downstate Medical Center, Brooklyn ,","place":["USA"]},{"name":"Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY ,","place":["USA"]},{"name":"Division of Cardiology, University of Colorado School of Medicine, Aurora, CO ,","place":["USA"]},{"name":"CPC (Colorado Prevention Center) Clinical Research, Aurora, CO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Cobbaert","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leiden University Medical Center, PO Box 9600, Leiden 2300 RC, The \u00a0","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera A","family":"Bittner","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schwertfeger","sequence":"additional","affiliation":[{"name":"Medical Affairs, Roche Diagnostics Int. Ltd, Rotkreuz ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Fazio","sequence":"additional","affiliation":[{"name":"Scientific Council, Cardiovascular and Metabolic Diseases, Regeneron Pharmaceuticals, Inc., Tarrytown, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun G","family":"Goodman","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta ,","place":["Canada"]},{"name":"Division of Cardiology, Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Harrington","sequence":"additional","affiliation":[{"name":"Dean, Weill Cornell Medicine, New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Stevanovic","sequence":"additional","affiliation":[{"name":"Dyslipidemia Medical Affairs, Sanofi, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey D","family":"White","sequence":"additional","affiliation":[{"name":"Green Lane Cardiovascular Research Unit, Te Whatu Ora\u2014Health New Zealand, Te Toka Tumai, and University of Auckland, Auckland ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Cit\u00e9, UMR 1148\/LVTS, FACT\/F-CRIN (French Alliance for Cardiovascular Trials), AP-HP, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Colorado School of Medicine, Aurora, CO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"2026102519522816100_ehag317-B1","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation","volume":"340","author":"Gabay","year":"1999","journal-title":"N Engl J Med"},{"key":"2026102519522816100_ehag317-B2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12916-019-1433-3","article-title":"Does low-density lipoprotein cholesterol induce inflammation? If so, does it matter? Current insights and future perspectives for novel therapies","volume":"17","author":"Jukema","year":"2019","journal-title":"BMC Med"},{"key":"2026102519522816100_ehag317-B3","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","article-title":"Interplay between inflammation and thrombosis in cardiovascular pathology","volume":"18","author":"Stark","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"2026102519522816100_ehag317-B4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"key":"2026102519522816100_ehag317-B5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/eurheartj\/eht367","article-title":"Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis","volume":"35","author":"Kaptoge","year":"2014","journal-title":"Eur Heart J"},{"key":"2026102519522816100_ehag317-B6","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.124.071269","article-title":"Relation of low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and lipoprotein(a) each to future cardiovascular events and death after acute coronary syndrome on high-intensity statin therapy: an analysis of the placebo arm of ODYSSEY OUTCOMES","volume":"151","author":"Steg","year":"2025","journal-title":"Circulation"},{"key":"2026102519522816100_ehag317-B7","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2026102519522816100_ehag317-B8","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1182\/blood-2003-11-3791","article-title":"Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro","volume":"103","author":"Kleemann","year":"2004","journal-title":"Blood"},{"key":"2026102519522816100_ehag317-B9","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.molimm.2005.06.045","article-title":"Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist","volume":"43","author":"Voleti","year":"2006","journal-title":"Mol Immunol"},{"key":"2026102519522816100_ehag317-B10","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2026102519522816100_ehag317-B11","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1161\/01.ATV.0000171992.36710.1e","article-title":"No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden\/human C-reactive protein transgenic mice","volume":"25","author":"Trion","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026102519522816100_ehag317-B12","doi-asserted-by":"publisher","first-page":"1237729","DOI":"10.3389\/fimmu.2023.1237729","article-title":"C-reactive protein: a target for therapy to reduce inflammation","volume":"14","author":"Rizo-T\u00e9llez","year":"2023","journal-title":"Front Immunol"},{"key":"2026102519522816100_ehag317-B13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3389\/fcvm.2017.00084","article-title":"An interleukin-6 receptor antibody suppresses atherosclerosis in atherogenic mice","volume":"4","author":"Akita","year":"2017","journal-title":"Front Cardiovasc Med"},{"key":"2026102519522816100_ehag317-B14","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis","volume":"379","author":"Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium","year":"2012","journal-title":"Lancet"},{"key":"2026102519522816100_ehag317-B15","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","author":"IL6R Genetics Consortium Emerging Risk Factors Collaboration","year":"2012","journal-title":"Lancet"},{"key":"2026102519522816100_ehag317-B16","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1177\/2047487318792626","article-title":"From lipoprotein apheresis to proprotein convertase subtilisin\/kexin type 9 inhibitors: impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients","volume":"25","author":"Zenti","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"2026102519522816100_ehag317-B17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jacc.2022.10.030","article-title":"PCSK9 inhibition during the inflammatory stage of SARS-CoV-2 infection","volume":"81","author":"Navarese","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026102519522816100_ehag317-B18","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur Heart J"},{"key":"2026102519522816100_ehag317-B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2018.04.136","article-title":"Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1\u03b2 in non-ST-elevation myocardial infarction","volume":"271","author":"Kleveland","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026102519522816100_ehag317-B20","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","article-title":"Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction","volume":"77","author":"Broch","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026102519522816100_ehag317-B21","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"2026102519522816100_ehag317-B22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/14779072.2025.2564137","article-title":"Anti-inflammatory strategies for patients with atherosclerotic coronary disease","volume":"23","author":"Imbesi","year":"2025","journal-title":"Expert Rev Cardiovasc Ther"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/40\/6008\/68386601\/ehag317.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/40\/6008\/68386601\/ehag317.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T23:52:35Z","timestamp":1792972355000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/40\/6008\/8692915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":22,"journal-issue":{"issue":"40","published-online":{"date-parts":[[2026,5,26]]},"published-print":{"date-parts":[[2026,10,26]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag317","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,21]]},"published":{"date-parts":[[2026,5,26]]}}}